Gill, Jagdeep http://orcid.org/0000-0002-6252-2125
Sayre, Eric C. http://orcid.org/0000-0002-4526-278X
Guermazi, Ali http://orcid.org/0000-0002-9374-8266
Nicolaou, Savvas http://orcid.org/0000-0002-4203-6605
Cibere, Jolanda http://orcid.org/0000-0003-2366-1226
Funding for this research was provided by:
Canadian Institutes of Health Research (#89890, #89997)
Canadian Arthritis Network (01-MNO-09N)
Arthritis Society (INS-12-027)
Article History
Received: 8 October 2021
Accepted: 19 October 2022
First Online: 28 October 2022
Declarations
:
: All study participants provided written informed consent. The study received ethics approval from the Clinical Research Ethics Board, University of British Columbia and was conducted in accordance with the declaration of Helsinki. (Ethics ID: H09–02046).
: Not applicable.
: JG, ECS, NS, and JC declare that they have no competing interests. AG’s competing interests include: Shareholder of BICL and LLC, and Consultant to MerckSerono, Pfizer, Novartis, TissueGene, Regeneron and AstraZeneca.